Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aptevo Therapeutics Inc. - Common Stock (NQ:APVO)

1.380 +0.382 (+38.26%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Aptevo Therapeutics Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Biofrontera (NASDAQ:BFRI) shares ... 
Via Benzinga
40 Stocks Moving In Wednesday's Mid-Day Session
Gainers Biofrontera Inc. (NASDAQ: BFRI) shares jumped 109.5% to $5.51 after Roth Capital initiated coverage on the stock with a Buy rating and a $20 price target. Longeveron Inc... 
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Ocuphire Pharma (NASDAQ:OCUP) stock rose 78.73% to $6.22 during Wednesday's pre-market session. The market value of their outstanding shares is at $107.6... 
Via Benzinga
28 Stocks Moving in Wednesday's Pre-Market Session
Gainers Engine Gaming and Media, Inc. (NASDAQ: GAME) rose 51% to $4.80 in pre-market trading after the company reported Q4 2021 and FY21 revenue was higher year over year.... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
We're starting the last day of this short holiday week with a dive into the biggest pre-market stock movers for Wednesday! 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Biolase (NASDAQ:BIOL) shares incr... 
Via Benzinga
56 Biggest Movers From Yesterday
Gainers Aptevo Therapeutics Inc. (NASDAQ: APVO) shares jumped 162.8% to close at $17.03 after the company announced a clinical update for its Phase 1b Expansion trial evaluating... 
Via Benzinga
Mid-Afternoon Market Update: Dow Surges 100 Points; Zoom Video Shares Plunge
Toward the end of trading Tuesday, the Dow traded up 0.29% to 35,723.97 while the NASDAQ fell 1.28% to 15,651.92. The S&P also fell, dropping 0.27% to 4,670.49. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Pasithea Therapeutics (NASDAQ:KTTA 
Via Benzinga
Mid-Day Market Update: Nasdaq Tumbles Over 200 Points; Pasithea Therapeutics Shares Surge
Midway through trading Tuesday, the Dow traded down 0.19% to 35,550.02 while the NASDAQ fell 1.45% to 15,624.16. The S&P also fell, dropping 0.63% to 4,653.33. The U.S. has... 
Via Benzinga
Topics Stocks
Exposures US Equities
36 Stocks Moving In Tuesday's Mid-Day Session
Gainers Pasithea Therapeutics Corp. (NASDAQ: KTTA) shares jumped 216.6% to $7.00 after the company announced its subsidiary Pasithea Clinics has been approved to provide... 
Via Benzinga
Mid-Morning Market Update: Markets Mostly Lower; Best Buy Posts Upbeat Q3 Earnings
Following the market opening Tuesday, the Dow traded up 0.02% to 35,627.53 while the NASDAQ fell 0.58% to 15,762.28. The S&P also fell, dropping 0.14% to 4,676.49. The U.S.... 
Via Benzinga
Topics Stocks
Exposures US Equities
Aptevo Stock Rallies After Posting First Complete Remission In Early Acute Myeloid Leukemia Trial
Aptevo Therapeutics Inc (NASDAQ: APVO) has announced a clinical update for its Phase 1b Expansion trial evaluating APVO436 for acute myeloid leukemia (AML). A high-... 
Via Benzinga
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
SEATTLE, WA / ACCESSWIRE / November 23, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers Dicerna Pharmaceuticals (NASDAQ:DRNA) shares moved upwards by 78.87% to $38.06 during Thursday's regular session. As of 12:30 EST, this security is trading at... 
Via Benzinga
70 Biggest Movers From Yesterday
Gainers Casper Sleep Inc. (NYSE: CSPR) shares jumped 88.5% to close at $6.69 on Monday after the company agreed to be acquired by Durational Capital Management. The... 
Via Benzinga
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
SEATTLE, WA / ACCESSWIRE / November 15, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Looking Into Aptevo Therapeutics's Return On Capital Employed
According to data from Benzinga Pro, during Q3, Aptevo Therapeutics's (NASDAQ:APVO) reported sales totaled $3.10 million. Despite a 16.99% increase in earnings, the company posted... 
Via Benzinga
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
SEATTLE, WA / ACCESSWIRE / November 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the "Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
Data support Advancement into the Clinic LUND, SWEDEN, and SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Alligator Bioscience AB ("Alligator") and Aptevo Therapeutics ("Aptevo") today announce... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
Preclinical data demonstrates inhibited tumor cell growth in vitro when paired with a T-cell engager bispecific SEATTLE, WA / ACCESSWIRE / November 11, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or the... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
SEATTLE, WA / ACCESSWIRE / October 27, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
SEATTLE, WA / ACCESSWIRE / October 26, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
Lead Clinical Candidate, APVO436, Recently Showed Clinical Activity and Acceptable Safety Profile in Adults with Myelodysplastic Syndrome (MDS) Article outlines a new strategy to employ APVO436 for... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Regencell Bioscience (NASDAQ:RGC)... 
Via Benzinga
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Phase 1 study showed some patients with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) achieved a remission with APVO436 after failing 1-8 lines of prior therapies - Data was... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
SEATTLE, WA / ACCESSWIRE / August 12, 2021 / Aptevo Therapeutics Inc. ("Aptevo" or "the Company") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
SEATTLE, WA / ACCESSWIRE / July 16, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
SEATTLE, WA / ACCESSWIRE / June 29, 2021 / Aptevo Therapeutics Inc. ("Aptevo") (NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immuno-oncology therapeutics based on... 
From Aptevo Therapeutics
Via AccessWire
Exposures COVID-19 Lead
12 Health Care Stocks Moving In Tuesday's Intraday Session
Gainers Anavex Life Sciences (NASDAQ:AVXL) stock increased by 17.07% to $25.92 during Tuesday's regular session. As of 12:33 EST, this security is trading at a volume... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.